Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393140 | 0.79 | KDM4E (0.46) | ALDH1A1HDAC8KDM4EHDAC1POLB | |
| SCHEMBL20816037 | 0.78 | PTGS2 (0.42) | ALDH1A1HDAC8CYP1A2CYP2C19PTGS2 | |
| SCHEMBL3387788 | 0.77 | HDAC8 (0.51) | ALDH1A1HDAC8CYP1A2CYP2C19KDM4E | |
| SCHEMBL5041467 | 0.76 | CYP1A2 (0.38) | ALDH1A1CYP1A2CYP2C19PTGS2KDM4E | |
| SCHEMBL16320824 | 0.73 | ALDH1A1 (0.42) | ALDH1A1HDAC8CYP1A2CYP2C19KDM4E | |
| SCHEMBL15996307 | 0.71 | RAPGEF4 (0.34) | HDAC8 | |
| SCHEMBL15866395 | 0.69 | CA1 (0.36) | HDAC8HDAC1 | |
| SCHEMBL20139218 | 0.69 | ALDH1A1 (0.38) | ALDH1A1HDAC8CYP1A2CYP2C19KDM4E | |
| SCHEMBL10565454 | 0.69 | ALDH1A1 (0.38) | ALDH1A1HDAC8CYP1A2CYP2C19KDM4E | |
| SCHEMBL22300409 | 0.68 | MEN1 (0.50) | HDAC8KDM4ESMN1; SMN2HDAC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1660487-B1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMA (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314885-B2 | Pyrrole compounds useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-01 | — | — | US | disclosed |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1660487-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | VERTEX PHARMACEUTICALS INCORPORATED | 2005-05-12 | — | — | US | disclosed |
| WO-2005016920-A1 | PYRROLE COMPOSITIONS USEFUL AS INHIBITORS OF C-MET | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101650-A1 | Pyrrole compositions useful as inhibitors of c-Met | MET, PRKCH, DMPK | ALDH1A1 3409/4885HDAC8 4253/4885CYP1A2 4341/4885 |
| US-20060173055-A1 | (4-(4-(2,3-difluorophenyl)-4H-1,2,4-triazol-3-yl)-1H-pyrrol-2-yl)(2H-pyrrol-1(5H)-yl)methanone; anticarcinogenic, antiproliferative and antimetastasis agent; inhibitors of c-Met protein kinase | MET, DMPK, CDK4 | ALDH1A1 1944/4885HDAC8 2730/4885CYP1A2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.